AN2 Therapeutics, Inc.
General ticker "ANTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $43.4M (TTM average)
AN2 Therapeutics, Inc. follows the US Stock Market performance with the rate: 28.8%.
Estimated limits based on current volatility of 4.0%: low 4.07$, high 4.41$
Factors to consider:
- Total employees count: 35 as of 2022
- Top business risk factors: Labor/talent shortage/retention, Limited operating history, Operational and conduct risks, Transition risks, Funding requirements
- Current price 102.1% above estimated high
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.70$, 2.08$]
- 2026-12-31 to 2027-12-31 estimated range: [0.69$, 2.04$]
Financial Metrics affecting the ANTX estimates:
- Positive: with PPE of -1.0 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 83.58 > -0.60
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of 0 <= 0
Short-term ANTX quotes
Long-term ANTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $69.64MM | $56.79MM | $38.11MM |
| Operating Income | $-69.64MM | $-56.79MM | $-38.11MM |
| Non-Operating Income | $4.90MM | $5.47MM | $2.94MM |
| R&D Expense | $54.87MM | $40.49MM | $24.77MM |
| Income(Loss) | $-64.73MM | $-51.32MM | $-35.17MM |
| Net Income(Loss)* | $-64.73MM | $-51.32MM | $-35.17MM |
| Stockholders Equity | $124.70MM | $81.85MM | $53.06MM |
| Assets | $138.74MM | $92.09MM | $61.95MM |
| Operating Cash Flow | $-53.29MM | $-49.26MM | $-29.83MM |
| Investing Cash Flow | $-43.28MM | $54.59MM | $28.31MM |
| Financing Cash Flow | $84.99MM | $0.37MM | $0.11MM |
| Earnings Per Share** | $-2.74 | $-1.72 | $-1.16 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.